Johannes Drach - Allgemeines Krankenhaus der Stadt Wien

基本信息

浏览量：235

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 282 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Figure 1 from Genome-Wide Transcriptional Response to 5-Aza-2′-deoxycytidine and Trichostatin A in Multiple Myeloma Cells

Gerwin Heller,Wolfgang M. Schmidt,Barbara Ziegler,Sonja Holzer,Leonhard Müllauer,Martin Bilban,Christoph C. Zielinski,Johannes Drach,Sabine Zöchbauer-Müller

crossref（2023）

引用0浏览0引用

1004OFinal overall survival results of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) vs R-CHOP in transplantation-ineligible patients (pts) with newly diagnosed mantle-cell lymphoma (MCL): A randomized, open-label, phase III (LYM-3002) study

Franco Cavalli, J Jin,H Pylypenko,G. Verhoef,Noppadol Siritanaratkul,J Drach,M Raderer,Jiri Mayer,J Pereira,G Tumyan,R Okamoto, S Nakahara,P Hu, C Appiani, S Nemat,Tadeusz Robak

ANNALS OF ONCOLOGY（2018）

引用1浏览0WOS引用

Efficacy and Safety of Frontline Rituximab, Cyclophosphamide, Doxorubicin and Prednisone Plus Bortezomib (VR-CAP) or Vincristine (R-CHOP) in a Subset of Newly Diagnosed Mantle Cell Lymphoma Patients Medically Eligible for Transplantation in the Randomized, Phase 3 LYM-3002 Study

Johannes Drach,Huiqiang Huang,Olga Samoilova,Andrew Belch,Charles Farber,Andre Bosly,Jan Novak,Jan Zaucha,Angela Dascalescu,Udomsak Bunworasate,Zvenyslava Masliak, Kateryna Vilchevskaya,Tadeusz Robak,Lixia Pei,Brendan Rooney,Helgi van de Velde,Franco Cavalli

Leukemia & lymphoma/Leukemia and lymphoma（2018）

引用14浏览0WOS引用

Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-Ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma: Final Overall Survival Results of a Randomised, Open-Label, Phase 3 Study

Tadeusz Robak,Jie Jin,Halyna Pylypenko,Gregor Verhoef,Noppadol Siritanaratkul,Johannes Drach,Markus Raderer,Jiri Mayer,Juliana Pereira,Gayane Tumyan,Rumiko Okamoto,Susumu Nakahara,Peter Hu,Carlos Appiani,Sepideh Nemat,Franco Cavalli

Lancet oncology/Lancet Oncologyno. 11 (2018): 1449-1458

引用89浏览0WOS引用

Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience

Doris Posch,Werner Rabitsch,Philipp Wohlfarth,Michael Leiner,Edit Porpaczy,Johannes Drach,Markus Raderer,Wolfgang Lamm

Oncologyno. 5 (2017): 295-301

引用4浏览0WOS引用

Long-term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/refractory Mantle Cell Lymphoma

Thomas E. Witzig,Pier Luigi Zinzani,Thomas M. Habermann,Joseph M. Tuscano,Johannes Drach,Radhakrishnan Ramchandren,Sevgi Kalayoglu Besisik,Kenichi Takeshita,Marie-Laure Casadebaig Bravo, Lei Zhang,Tommy Fu,Andre Goy

American journal of hematology（2017）

引用19浏览0WOS引用

Association Between Quality Of Response And Outcomes In Patients With Newly Diagnosed Mantle Cell Lymphoma Receiving Vr-Cap Versus R-Chop In The Phase 3 Lym-3002 Study

Gregor Verhoef,Tadeusz Robak,Huiqiang Huang,Halyna Pylypenko,Noppadol Siritanaratkul,Juliana Pereira,Johannes Drach,Jiri Mayer,Rumiko Okamoto,Lixia Pei,Brendan Rooney,Andrew Cakana,Helgi Van De Velde,Franco Cavalli

HAEMATOLOGICA（2017）

引用4浏览0WOS引用

IMPACT OF STABLE DISEASE OR BETTER RESPONSES TO LENALIDOMIDE ON SURVIVAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: MCL-001 (EMERGE) AND MCL-002 (SPRINT) STUDIES

A. Goy,L. Arcaini,M. E. Williams,T. Lamy,S. K. Besisik,J. Drach,R. Ramchandren,T. E. Witzig,T. Fu,L. Zhang,T. Biyukov,E. Barnett,M. L. Casadebaig Bravo,M. Trneny

HAEMATOLOGICA（2016）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn